ECSP14005678A - Composiciones y métodos para tratar el virus de la hepatitis c - Google Patents

Composiciones y métodos para tratar el virus de la hepatitis c

Info

Publication number
ECSP14005678A
ECSP14005678A ECIEPI20145678A ECPI201405678A ECSP14005678A EC SP14005678 A ECSP14005678 A EC SP14005678A EC IEPI20145678 A ECIEPI20145678 A EC IEPI20145678A EC PI201405678 A ECPI201405678 A EC PI201405678A EC SP14005678 A ECSP14005678 A EC SP14005678A
Authority
EC
Ecuador
Prior art keywords
virus
subject
methods
effective amount
hepatitis
Prior art date
Application number
ECIEPI20145678A
Other languages
English (en)
Inventor
Charles Reynolds
Rowchanak Pakdaman
Christy Hebner
Reza Oliyai
Adrian Ray
Robert Hindes
William Symonds
Vahid Zia
Dimitrios Stefanidis
Hongmei Mo
Miriam Berrey
Darryl Cleary
Melissa Casteel
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of ECSP14005678A publication Critical patent/ECSP14005678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

En el presente documento se divulga una composición y forma de dosificación unitaria para el tratamiento de una infección causada por el virus de la hepatitis C (VHC) que comprende GS-7977 y al menos un excipiente farmacéuticamente aceptable, así como también los métodos para la fabricación de dicha composición y forma de dosificación unitaria. También en el presente documento se divulga un método para tratar a un sujeto, preferentemente un ser humano, infectado con el virus de la hepatitis C, dicho método comprende administrar al sujeto durante un período de tiempo una cantidad efectiva de GS-7977 y una cantidad efectiva de ribavirina. En un aspecto, el método comprende administrar al sujeto un régimen de tratamiento libre de interferón que comprende una cantidad efectiva de GS-7977 y una cantidad efectiva de ribavirina. En un aspecto particular, el método es suficiente para producir en el sujeto una cantidad indetectable de ARN del VHC durante al menos 12 semanas después de finalizado el período de tiempo.
ECIEPI20145678A 2011-11-29 2014-06-18 Composiciones y métodos para tratar el virus de la hepatitis c ECSP14005678A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
ECSP14005678A true ECSP14005678A (es) 2015-12-31

Family

ID=56291296

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20145678A ECSP14005678A (es) 2011-11-29 2014-06-18 Composiciones y métodos para tratar el virus de la hepatitis c

Country Status (22)

Country Link
EP (2) EP3777867A1 (es)
JP (2) JP5899327B2 (es)
KR (1) KR101560994B1 (es)
CN (1) CN104039319B (es)
AR (1) AR089578A1 (es)
AU (1) AU2012346217B2 (es)
BR (1) BR112014012739A8 (es)
CA (1) CA2856529C (es)
CO (1) CO6970603A2 (es)
EA (1) EA027296B1 (es)
EC (1) ECSP14005678A (es)
ES (1) ES2817886T3 (es)
HK (1) HK1202268A1 (es)
MD (1) MD4430C1 (es)
MX (1) MX2014006373A (es)
PE (1) PE20141296A1 (es)
PH (1) PH12014501133A1 (es)
SG (1) SG11201402609RA (es)
TW (1) TWI566773B (es)
UY (1) UY34474A (es)
WO (1) WO2013082003A1 (es)
ZA (1) ZA201404061B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Pharmasset Llc Methods for treating HCV
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
US20170080008A1 (en) * 2014-03-05 2017-03-23 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
WO2015191945A2 (en) * 2014-06-13 2015-12-17 Ratiopharm Gmbh Solid state forms of sofosbuvir
EA201692514A1 (ru) * 2014-06-23 2017-04-28 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
WO2015197549A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of sofosbuvir and ribavirin
EP2959901A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of sofosbuvir and ribavirin
CN105267232A (zh) * 2014-06-30 2016-01-27 康普药业股份有限公司 一种用于治疗丙型肝炎的药物制剂及其制备方法
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
US20170296570A1 (en) * 2014-10-08 2017-10-19 Sandoz Ag High Drug Load Tablets Comprising Sofosbuvir
CN104546783A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种索非布韦薄膜包衣片制剂及其制备方法
CN104622836B (zh) * 2014-12-23 2020-02-21 浙江华海药业股份有限公司 索非布韦包衣片剂及其制备方法
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
WO2016156330A1 (en) * 2015-03-30 2016-10-06 Ratiopharm Gmbh Solid pharmaceutical composition comprising amorphous sofosbuvir and a phospholipid
CN104840964B (zh) * 2015-05-07 2018-01-16 南京正大天晴制药有限公司 一种稳定的索氟布韦药物组合物及其制备方法
CZ2015443A3 (cs) 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
CN104906062B (zh) * 2015-06-30 2018-05-25 浙江天顺生物科技有限公司 一种索非布韦的片剂及其制备方法
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CA3033858A1 (en) 2016-08-19 2018-02-22 Sandoz Ag Sofosbuvir derivatives for the treatment of hepatitis c
CZ2016553A3 (cs) 2016-09-09 2018-03-21 Zentiva, K.S. Pevná farmaceutická dávková forma obsahující sofosbuvir
CN106667936B (zh) * 2016-12-31 2021-02-05 江苏科本药业有限公司 一种索非布韦片剂及其制备方法
CN107041873B (zh) * 2017-02-17 2020-02-28 杭州青玥医药科技有限公司 索氟布韦包衣片剂的制备方法
CN106880642B (zh) * 2017-02-17 2019-08-06 杭州青玥医药科技有限公司 索氟布韦药物组合物及其制备方法
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN110604726B (zh) * 2019-07-19 2022-06-07 株洲千金药业股份有限公司 一种索非布韦组合物及其应用
CN111072742B (zh) * 2019-12-23 2022-12-02 南京正大天晴制药有限公司 一种治疗丙肝药物的新晶型及其组合物
CN111973566A (zh) * 2020-07-23 2020-11-24 石药集团中奇制药技术（石家庄）有限公司 一种索磷布韦片

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
EP2495249A1 (en) * 2007-02-26 2012-09-05 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20100226885A1 (en) * 2007-09-14 2010-09-09 Albrecht Janice K Method of treating hepatitis c patients
DE102007052070A1 (de) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
DE102008057284A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
EP2350114A1 (en) * 2008-11-20 2011-08-03 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
DE102009015702A1 (de) * 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) * 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2467144A1 (en) * 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
BR112012024884A2 (pt) * 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype

Also Published As

Publication number Publication date
CN104039319A (zh) 2014-09-10
KR101560994B1 (ko) 2015-10-15
PH12014501133B1 (en) 2014-09-01
CO6970603A2 (es) 2014-06-13
EP2785340A1 (en) 2014-10-08
TW201325599A (zh) 2013-07-01
BR112014012739A8 (pt) 2017-06-20
EA201490903A1 (ru) 2014-11-28
TWI566773B (zh) 2017-01-21
MX2014006373A (es) 2014-07-22
ZA201404061B (en) 2016-09-28
MD4430C1 (ro) 2017-03-31
JP2014533733A (ja) 2014-12-15
JP5899327B2 (ja) 2016-04-06
AU2012346217B2 (en) 2016-02-04
MD4430B1 (ro) 2016-08-31
SG11201402609RA (en) 2014-06-27
EP3777867A1 (en) 2021-02-17
UY34474A (es) 2013-06-28
MD20140058A2 (en) 2014-11-30
WO2013082003A1 (en) 2013-06-06
CA2856529C (en) 2018-03-06
EP2785340B1 (en) 2020-07-15
PE20141296A1 (es) 2014-10-08
NZ625532A (en) 2016-07-29
AR089578A1 (es) 2014-09-03
EA027296B1 (ru) 2017-07-31
BR112014012739A2 (pt) 2017-06-13
HK1202268A1 (en) 2015-09-25
KR20140108645A (ko) 2014-09-12
ES2817886T3 (es) 2021-04-08
AU2012346217A1 (en) 2014-06-19
PH12014501133A1 (en) 2014-09-01
JP2016053096A (ja) 2016-04-14
CN104039319B (zh) 2017-12-29
CA2856529A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
ECSP14005678A (es) Composiciones y métodos para tratar el virus de la hepatitis c
AR088580A1 (es) Metodos y composiciones para tratar el virus de la hepatitis c
CO6592102A2 (es) Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
ECSP12012067A (es) Inhibidores del virus de la hepatitis c
ECSP14013315A (es) Inhibidores de aplicación viral
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
UY37997A (es) Agentes antivirales contra la hepatitis b
EA201391519A1 (ru) 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
ECSP12011845A (es) Nuevos inhibidores macrocíclicos de la replicación
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
CL2012001960A1 (es) Compuestos derivados de ácido tiofeno-2-carboxílico; inhibidores de virus flaviviridae; composición farmacéutica que los comprende; utiles en el tratamiento de la hepatitis c. pct fase nacional
AR076570A1 (es) Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas
ECSP12011610A (es) Inhibidores de la replicación de los virus de la gripe
EA201390822A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
ECSP13012622A (es) Compuestos antivirales
EA201301335A1 (ru) Замещенные алифаны, циклофаны, гетерафаны, гетерофаны, гетеро-гетерафаны и металлоцены, пригодные для использования при лечении инфекции вгс
UY33897A (es) Inhibidores del virus de la hepatitis c
MX2018013782A (es) Antigenos y vacunas dirigidos contra enterovirus humanos.
GT201500046A (es) Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d
EA201200890A1 (ru) Комбинированная терапия hcv
UY34066A (es) Inhibidores del virus de la hepatitis c
IN2012MN02896A (es)
ECSP21087299A (es) Composiciones y métodos para tratar el virus de la hepatitis c
UA114097C2 (xx) Композиція (варіанти) та спосіб (варіанти) лікування вірусного гепатиту с
CR20140273A (es) Composiciones y métodos para tratar el virus de la hepatitis c